Do analysts prefer ELMD or DXR?

Electromed currently has a consensus price target of $43.75, indicating a potential upside of 55.69%. Given Electromed's stronger consensus rating and higher possible upside, research analysts clearly believe Electromed is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, ELMD or DXR?

Electromed has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.19 $5.15M $1.31 21.45 Daxor N/A N/A N/A N/A N/A

Is ELMD or DXR more profitable?

Electromed has a net margin of 11.34% compared to Daxor's net margin of 0.00%. Electromed's return on equity of 15.71% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% Daxor N/A N/A N/A

Does the media favor ELMD or DXR?

In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.84 beat Daxor's score of 0.00 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DXR or PDEX?

Pro-Dex has a consensus target price of $74.00, suggesting a potential upside of 15.50%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts clearly believe Pro-Dex is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Pro-Dex 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has better valuation and earnings, DXR or PDEX?

Pro-Dex has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Pro-Dex $77.55M 2.64 $13.66M $4.13 15.51

Is DXR or PDEX more profitable?

Pro-Dex has a net margin of 17.62% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 25.13% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Pro-Dex 17.62% 25.13% 16.02%

Do analysts prefer STIM or DXR?

Neuronetics presently has a consensus price target of $4.67, suggesting a potential upside of 116.05%. Given Neuronetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neuronetics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation & earnings, STIM or DXR?

Daxor has lower revenue, but higher earnings than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $155.10M 1.06 -$39M -$0.44 N/A Daxor N/A N/A N/A N/A N/A

Is STIM or DXR more profitable?

Daxor has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Daxor's return on equity of 0.00% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% Daxor N/A N/A N/A

Do analysts prefer PROF or DXR?

Profound Medical presently has a consensus price target of $11.50, suggesting a potential upside of 96.92%. Given Profound Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Profound Medical is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, PROF or DXR?

Daxor has lower revenue, but higher earnings than Profound Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $16.10M 13.26 -$42.57M -$0.98 N/A Daxor N/A N/A N/A N/A N/A

Does the media prefer PROF or DXR?

In the previous week, Profound Medical and Profound Medical both had 1 articles in the media. Profound Medical's average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend FOCL or DXR?

FocalTherics currently has a consensus price target of $7.75, suggesting a potential upside of 84.52%. Given FocalTherics' higher probable upside, research analysts clearly believe FocalTherics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FocalTherics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, FOCL or DXR?

Daxor has lower revenue, but higher earnings than FocalTherics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $70.53M 2.23 -$29.25M -$1.03 N/A Daxor N/A N/A N/A N/A N/A

Is FOCL or DXR more profitable?

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -56.26%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% Daxor N/A N/A N/A

Daxor (DXR) Competitors

$10.62 -0.36 (-3.28%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$10.73 +0.11 (+1.04%)

As of 10/2/2026 04:04 PM Eastern

Compare

DXR vs. ELMD, PDEX, STIM, PROF, and FOCL

Should you buy Daxor stock or one of its competitors? Daxor's main competitors and comparable companies include Electromed (ELMD), Pro-Dex (PDEX), Neuronetics (STIM), Profound Medical (PROF), and FocalTherics (FOCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Daxor compare to Electromed?

Electromed (NYSE:ELMD) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.84 beat Daxor's score of 0.00 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Electromed has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.19	$5.15M	$1.31	21.45
Daxor	N/A	N/A	N/A	N/A	N/A

Electromed currently has a consensus price target of $43.75, indicating a potential upside of 55.69%. Given Electromed's stronger consensus rating and higher possible upside, research analysts clearly believe Electromed is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

40.8% of Electromed shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 51.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Electromed has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Daxor has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Electromed has a net margin of 11.34% compared to Daxor's net margin of 0.00%. Electromed's return on equity of 15.71% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Daxor	N/A	N/A	N/A

Summary

Electromed beats Daxor on 10 of the 11 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Daxor has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

Pro-Dex has a consensus target price of $74.00, suggesting a potential upside of 15.50%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts clearly believe Pro-Dex is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Pro-Dex has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Pro-Dex	$77.55M	2.64	$13.66M	$4.13	15.51

1.3% of Daxor shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 51.5% of Daxor shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pro-Dex has a net margin of 17.62% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 25.13% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Pro-Dex	17.62%	25.13%	16.02%

In the previous week, Daxor had 1 more articles in the media than Pro-Dex. MarketBeat recorded 1 mentions for Daxor and 0 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.50 beat Daxor's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Daxor	Neutral
Pro-Dex	Positive

Summary

Pro-Dex beats Daxor on 9 of the 12 factors compared between the two stocks.

How does Daxor compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Daxor has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Daxor's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Daxor	N/A	N/A	N/A

In the previous week, Daxor had 1 more articles in the media than Neuronetics. MarketBeat recorded 1 mentions for Daxor and 0 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company	Overall Sentiment
Neuronetics	Neutral
Daxor	Neutral

Daxor has lower revenue, but higher earnings than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$155.10M	1.06	-$39M	-$0.44	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Neuronetics presently has a consensus price target of $4.67, suggesting a potential upside of 116.05%. Given Neuronetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neuronetics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neuronetics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Daxor has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Summary

Neuronetics beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profound Medical has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Daxor has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Daxor has a net margin of 0.00% compared to Profound Medical's net margin of -171.57%. Daxor's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
Daxor	N/A	N/A	N/A

Profound Medical presently has a consensus price target of $11.50, suggesting a potential upside of 96.92%. Given Profound Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Profound Medical is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Profound Medical and Profound Medical both had 1 articles in the media. Profound Medical's average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Daxor has lower revenue, but higher earnings than Profound Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	13.26	-$42.57M	-$0.98	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

Profound Medical beats Daxor on 6 of the 10 factors compared between the two stocks.

How does Daxor compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

FocalTherics currently has a consensus price target of $7.75, suggesting a potential upside of 84.52%. Given FocalTherics' higher probable upside, research analysts clearly believe FocalTherics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

FocalTherics has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Daxor has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -56.26%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
Daxor	N/A	N/A	N/A

In the previous week, Daxor had 1 more articles in the media than FocalTherics. MarketBeat recorded 1 mentions for Daxor and 0 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company	Overall Sentiment
FocalTherics	Neutral
Daxor	Neutral

Daxor has lower revenue, but higher earnings than FocalTherics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.23	-$29.25M	-$1.03	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

Daxor beats FocalTherics on 7 of the 11 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.10M	$5.48B	$7.14B	$13.10B
Dividend Yield	N/A	1.81%	2.54%	16.77%
P/E Ratio	N/A	24.55	273.67	26.04
Price / Sales	N/A	67.29	602.53	86.50
Price / Cash	N/A	32.43	77.60	51.75
Price / Book	N/A	5.68	10.92	6.30
Net Income	N/A	$152.11M	$3.50B	$361.43M
7 Day Performance	-4.67%	-2.01%	-2.11%	-1.67%
1 Month Performance	1.96%	-5.42%	-6.34%	-3.94%
1 Year Performance	-24.14%	2.75%	8.81%	2.77%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	0.9511 of 5 stars	$10.62 -3.3%	N/A	-24.1%	$64.10M	N/A	N/A	37	News Coverage Positive News
ELMD Electromed	3.3146 of 5 stars	$27.66 +0.3%	$43.75 +58.2%	+13.7%	$233.37M	$73.78M	37.19	197	News Coverage
PDEX Pro-Dex	3.4384 of 5 stars	$72.64 -0.5%	$74.00 +1.9%	+90.7%	$232.70M	$77.55M	17.59	206
STIM Neuronetics	3.7482 of 5 stars	$2.79 -1.1%	$4.67 +67.3%	-19.1%	$213.74M	$149.16M	N/A	658
PROF Profound Medical	1.7813 of 5 stars	$5.75 +2.7%	$11.50 +99.9%	+10.0%	$208.40M	$16.10M	N/A	162

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors